JP6039428B2 - 抗ｈｅｒ２抗体および組成物 - Google Patents

抗ｈｅｒ２抗体および組成物 Download PDF

Info

Publication number
JP6039428B2
JP6039428B2 JP2012555532A JP2012555532A JP6039428B2 JP 6039428 B2 JP6039428 B2 JP 6039428B2 JP 2012555532 A JP2012555532 A JP 2012555532A JP 2012555532 A JP2012555532 A JP 2012555532A JP 6039428 B2 JP6039428 B2 JP 6039428B2
Authority
JP
Japan
Prior art keywords
antibody
light chain
heavy
variable region
her2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012555532A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013520984A5 (enExample
JP2013520984A (ja
Inventor
ミッケル・ヴァンダール・ペダーセン
アラン・イェンセン
ペル−ヨハン・メイイェル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Servier Symphogen AS
Original Assignee
Symphogen AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symphogen AS filed Critical Symphogen AS
Publication of JP2013520984A publication Critical patent/JP2013520984A/ja
Publication of JP2013520984A5 publication Critical patent/JP2013520984A5/ja
Application granted granted Critical
Publication of JP6039428B2 publication Critical patent/JP6039428B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2012555532A 2010-03-04 2011-03-03 抗ｈｅｒ２抗体および組成物 Expired - Fee Related JP6039428B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US31055210P 2010-03-04 2010-03-04
DKPA201070085 2010-03-04
US61/310,552 2010-03-04
DKPA201070085 2010-03-04
US35413310P 2010-06-11 2010-06-11
US61/354,133 2010-06-11
US201061428014P 2010-12-29 2010-12-29
US61/428,014 2010-12-29
PCT/IB2011/050903 WO2011107957A1 (en) 2010-03-04 2011-03-03 Anti-her2 antibodies and compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016123623A Division JP2016182135A (ja) 2010-03-04 2016-06-22 抗ｈｅｒ２抗体および組成物

Publications (3)

Publication Number Publication Date
JP2013520984A JP2013520984A (ja) 2013-06-10
JP2013520984A5 JP2013520984A5 (enExample) 2014-04-24
JP6039428B2 true JP6039428B2 (ja) 2016-12-07

Family

ID=44541704

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012555532A Expired - Fee Related JP6039428B2 (ja) 2010-03-04 2011-03-03 抗ｈｅｒ２抗体および組成物

Country Status (5)

Country Link
EP (1) EP2542589A4 (enExample)
JP (1) JP6039428B2 (enExample)
CN (1) CN102884084B (enExample)
TW (1) TW201141519A (enExample)
WO (1) WO2011107957A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2337800B1 (en) 2008-09-15 2013-10-02 Yeda Research and Development Co. Ltd. Antibody combinations and use of same for treating cancer
WO2012059857A2 (en) * 2010-11-01 2012-05-10 Symphogen A/S Pan-her antibody composition
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
US9040047B2 (en) 2011-05-16 2015-05-26 Yeda Research And Development Co. Ltd. Combinations of anti ErbB antibodies for the treatment of cancer
HK1202431A1 (en) 2012-05-02 2015-10-02 Symphogen A/S Humanized pan-her antibody compositions
PL3489261T3 (pl) 2012-08-24 2021-08-16 The Regents Of The University Of California Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
PT3480215T (pt) * 2013-11-19 2021-07-05 Remegen Ltd Anticorpo anti-her2 e seu conjugado
CN104974261B (zh) * 2014-04-01 2019-06-14 三生国健药业（上海）股份有限公司 重组抗her2/ps双特异性抗体、其制备方法和应用
BR112017011170A2 (pt) * 2014-12-18 2018-02-27 Hoffmann La Roche método para determinar a citotoxicidade dependente do complemento de uma composição
CN106831987B (zh) * 2015-12-04 2020-01-21 浙江大学 一种抗人her2抗体及其编码基因和应用
CN109154600A (zh) * 2016-06-16 2019-01-04 豪夫迈·罗氏有限公司 用于确定cdc诱导抗体的测定法和方法
KR20230047507A (ko) 2016-06-27 2023-04-07 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 암 치료 조합
CN107137424B (zh) * 2017-05-15 2024-12-17 广州领晟医疗科技有限公司 一种利用正常小鼠建立her2阳性肿瘤的动物模型的方法
AU2019235634A1 (en) * 2018-03-13 2020-10-22 Zymeworks Bc Inc. Anti-HER2 biparatopic antibody-drug conjugates and methods of use
CN111655295B (zh) 2018-08-29 2024-05-28 荣昌生物制药(烟台)股份有限公司 抗her2抗体药物偶联物在治疗尿路上皮癌中的用途
CN109134656A (zh) * 2018-09-12 2019-01-04 四川妙和生物科技有限公司 一种抗her2多克隆抗体
WO2020188836A1 (ja) * 2019-03-15 2020-09-24 公益財団法人がん研究会 抗ポドプラニン抗体
EP3941947A4 (en) * 2019-03-22 2022-12-14 Olivia Newton-John Cancer Research Institute ANTI-HER2 BINDING MOLECULES

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794128B2 (en) * 1998-04-24 2004-09-21 The Regents Of The University Of California Methods of selecting internalizing antibodies
US7244826B1 (en) * 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
EP1572972A4 (en) * 2002-11-21 2007-11-21 Genentech Inc THERAPY OF NON-MALIGNER DISEASES OR DISORDER WITH ANTI-ERBB2 ANTIBODIES
GB0503546D0 (en) * 2005-02-21 2005-03-30 Hellenic Pasteur Inst Antibody
US7498142B2 (en) * 2006-01-31 2009-03-03 Yeda Research And Development Co., Ltd. Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies
MX2011001927A (es) * 2008-08-29 2011-04-21 Symphogen As Composiciones de anticuerpo recombinante anti-receptor de factor de crecimiento epidermico.

Also Published As

Publication number Publication date
CN102884084A (zh) 2013-01-16
EP2542589A1 (en) 2013-01-09
TW201141519A (en) 2011-12-01
JP2013520984A (ja) 2013-06-10
CN102884084B (zh) 2016-12-07
WO2011107957A1 (en) 2011-09-09
EP2542589A4 (en) 2013-08-07

Similar Documents

Publication Publication Date Title
US8609095B2 (en) Anti-HER2 antibodies and compositions
JP7736772B2 (ja) ＥＧＦＲ及びｃＭＥＴに結合する抗体
US10221246B2 (en) Pan-HER antibody composition
CA2816519C (en) Pan-her antibody composition
CN102884084B (zh) 抗her2抗体及组合物
JP2022071071A (ja) ＥｒｂＢ－２およびＥｒｂＢ－３に結合する抗体
EP4190819A1 (en) Pharmaceutical combination containing anti-pd-1-anti-vegfa bispecific antibody, and use thereof
EP2331577A2 (en) Recombinant anti-epidermal growth factor receptor antibody compositions
EP4180457A1 (en) Anti-cldn-18.2 antibody and use thereof
JP2016182135A (ja) 抗ｈｅｒ２抗体および組成物
EP4678186A1 (en) Pharmaceutical composition comprising anti-ctla4-anti-pd-1 bispecific antibody and use thereof
HK40091003A (en) Pharmaceutical combination containing anti-pd-1-anti-vegfa bispecific antibody, and use thereof

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20140120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140228

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150407

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150702

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150805

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150907

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160622

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160805

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20161011

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161104

R150 Certificate of patent or registration of utility model

Ref document number: 6039428

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees